Abstract
To study the distributed characteristics of KIR2DL1 alleles frequencies and the recognition HLA-C ligand in the Chinese Han population. The 111 patients and 116 donors from CMDP were performed the KIR2DL1 high-resolution typing and KIR genotyping using sequence-based testing (SBT) and PCR-SSP methods. A total of 224 individuals with KIR2DL1 locus was predominantly observed and accounted for 98.68% (224/227). There were 3 difference KIR2DL1 alleles, include of KIR2DL1 ∗ 00302, ∗ 00201 and ∗ 00401 alleles polymorphism. The most commonly of phenotype frequency were observed KIR2DL1 ∗ 00302(84.82%, 380/448), KIR2DL1 ∗ 00201 (12.05%, 54/448) and KIR2DL1 ∗ 00401 (3.13%, 14/448), present at allele genetype frequencies of 61.04%, 6.22% and 1.58%. The allele homozygotic type of KIR2DL1 ∗ 00302 and KIR2DL1 ∗ 00302 was the most frequency in the six gene complex of KIR2DL1 allele by high resolution typing. The allele heterozygous type of KIR2DL1 ∗ 00302 and KIR2DL1 ∗ 00401 had present statistically significant difference in haplotypes A/A and B/x( P = 0.001), and KIR2DL1 ∗ 00401 was lacked all A/A haplotype. The KIR2DL1 ∗ 00302 and KIR2DL1 ∗ 00201 allele had significant positive associations between different KIR pairs of KIR2DS1,KIR2DS4,KIR2DS5,KIR2DL3 and KIR3DL1/S1 using linkage disequilibrium analysis ( P ⩽ 0.001), respectively. In the receptor-ligand of KIR/HLA model after allo-HSCT, KIR2DL1 ∗ 00302 alleles and their HLA-C2 group ligands had correlation. KIR2DL1 ∗ 00302 and HLA-C ∗ 06:02 was the most common of combination ligand model, but KIR2DL1 ∗ 00302 and HLA-C ∗ 01:02 was the most frequent mismatch ligand model that it could be develop of NK cell-induced alloreactivity, meanwhile there was statistically significant difference of frequency distribution ( P < 0.05). The KIR2DL1 ∗ 00302 is the most frequency allele in Chinese Han population. The KIR2DL1 high resolution typing would be beneficial for predicting donor NK cells alloactivity after hematopoietic stem cell transplantation and selecting suitable donors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
